Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 17, 2007

Novartis to Potentially Spend $500M on Osteoporosis Drug

  • Radius Health granted Novartis an option to obtain an exclusive worldwide license, excluding Japan, to its osteoporosis compound. The deal is worth over $375 million for Radius and $125 million to Ipsen, the original holder of the rights pertaining to BA058. This Phase II candidate is a PTHrP (parathyroid hormone-related protein) analogue.

    If Novartis exercises its right, Radius stands to earn $500 million in upfront and milestone-based fees plus royalties. Novartis will then assume the global clinical development, manufacturing, and marketing of BA058 in all regions except Japan. Radius has retained the option to co-commercialize the medication in the U.S.

    Of the amount received from Novartis, Radius will, in turn, pay Ipsen up to $125 million related to the achievement of certain milestones as well as royalties. In September 2005 Radius gained a worldwide license to the candidate excluding Japan. Teijin previously acquired Japanese rights to the product from Ipsen.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »